RCUS - Arcus Biosciences Inc Stock Price, Fair Value and News

$25.62+0.19 (+0.75%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

RCUS Price Action

Last 7 days

0.2%

Last 30 days

25.9%

Last 90 days

121.6%

Trailing 12 Months

55.8%

RCUS RSI Chart

RCUS Valuation

Market Cap

2.8B

Price/Earnings (Trailing)

-8.11

Price/Sales (Trailing)

11.53

EV/EBITDA

-7.96

Price/Free Cashflow

-5.96

RCUS Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

RCUS Fundamentals

RCUS Revenue

Revenue (TTM)

240.0M

Rev. Growth (Yr)

-45.83%

Rev. Growth (Qtr)

-83.75%

RCUS Earnings

Earnings (TTM)

-341.0M

Earnings Growth (Yr)

-46.74%

Earnings Growth (Qtr)

100%

RCUS Profitability

EBT Margin

-141.67%

Return on Equity

-78.21%

Return on Assets

-35.01%

Free Cashflow Yield

-16.77%

RCUS Investor Care

Shares Dilution (1Y)

17.99%

Diluted EPS (TTM)

-3.46

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2025	141.0M	262.0M	240.0M	0
2024	237.0M	247.0M	263.0M	258.0M
2023	119.0M	121.0M	120.0M	117.0M
2022	391.5M	409.1M	432.6M	112.0M
2021	85.7M	93.4M	38.4M	383.0M
2020	15.0M	15.0M	77.8M	78.0M
2019	8.9M	9.4M	6.8M	15.0M
2018	2.7M	3.9M	8.0M	8.4M
2017	0	0	0	1.4M

Get all data in R, Python etc through our Historical Stock Data APIs

About Arcus Biosciences Inc

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT investigational monoclonal antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.

CEO	Dr. Terry J. Rosen Ph.D.
WEBSITE	arcusbio.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	500

Arcus Biosciences Inc Frequently Asked Questions

What is the ticker symbol for Arcus Biosciences Inc? What does RCUS stand for in stocks?

RCUS is the stock ticker symbol of Arcus Biosciences Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Arcus Biosciences Inc (RCUS)?

As of Wed Dec 03 2025, market cap of Arcus Biosciences Inc is 2.77 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of RCUS stock?

You can check RCUS's fair value in chart for subscribers.

Is Arcus Biosciences Inc a good stock to buy?

The fair value guage provides a quick view whether RCUS is over valued or under valued. Whether Arcus Biosciences Inc is cheap or expensive depends on the assumptions which impact Arcus Biosciences Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for RCUS.

What is Arcus Biosciences Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Dec 03 2025, RCUS's PE ratio (Price to Earnings) is -8.11 and Price to Sales (PS) ratio is 11.53. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. RCUS PE ratio will change depending on the future growth rate expectations of investors.